Close Menu

NEW YORK (360Dx) – Co-Diagnostics ended its first day as a public traded firm with its shares down about 3 percent on the Nasdaq.

The firm went public on Wednesday with an offering of more than 1.1 million shares at $6 per share. Trading on the Nasdaq Capital Market under ticker symbol CODX, its shares ended the day at $5.81 per share.

Total gross proceeds from IPO was $7.1 million, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.

The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.

Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.

In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.